Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from https://aidsinfo.nih.gov/guidelines on 5/4/2020

Visit the AIDSinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
What to Start: Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children  

(last updated April 14, 2020; last reviewed April 14, 2020)

Panel’s Recommendations

- The selection of an initial regimen should be individualized based on several factors, including the characteristics of the proposed regimen, the patient's characteristics, drug efficacy, potential adverse effects, patient and family preferences, and the results of viral resistance testing (AIII).
- For treatment-naive children, the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) recommends initiating antiretroviral therapy with three drugs: a dual-nucleoside/nucleotide reverse transcriptase inhibitor backbone plus an integrase strand transfer inhibitor, a non-nucleoside reverse transcriptase inhibitor, or a boosted protease inhibitor (AI*).
- Table 7 provides a list of Panel-recommended regimens that are designated as Preferred or Alternative; recommendations vary by a patient's age, weight, and sexual maturity rating.

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

† Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents

Criteria Used for Recommendations

In general, the recommendations of the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) are based on reviews of pediatric and adult clinical trial data published in peer-reviewed journals, data prepared by manufacturers for Food and Drug Administration (FDA) review, and data presented in abstract format at major scientific meetings. Few randomized, Phase 3 clinical trials of antiretroviral therapy (ART) in pediatric patients have directly compared different treatment regimens. Most pediatric drug data come from Phase 1/2 safety and pharmacokinetic (PK) trials and nonrandomized, open-label studies. In general, even in studies of adults, assessment of drug efficacy and potency is primarily based on surrogate marker endpoints, such as CD4 T lymphocyte (CD4) cell count and viral load. The Panel continually modifies recommendations on optimal initial therapy for children as new data become available, new therapies or drug formulations are developed, and additional toxicities are recognized.

When developing recommendations for specific drugs or regimens, the Panel considers the following information:

- Data demonstrating durable viral suppression, immunologic improvement, and clinical improvement (when available) with the drug or regimen, preferably in children as well as adults;
- The extent of pediatric experience with a specific drug or regimen;
- The incidence and types of short-term and long-term drug toxicity in people who are taking the drug or regimen, focusing on toxicities that are reported in children;
- The availability and acceptability of formulations that are appropriate for pediatric use, including palatability, ease of preparation (e.g., syrups vs. powders), pill size, and the number of pills or volume of oral solution needed for an appropriate dose;
- Dosing frequency and food and fluid requirements; and
- The potential for drug interactions with other medications.
The Panel classifies recommended drugs or drug combinations into one of two categories:

- **Preferred**: Drugs or drug combinations are designated as Preferred for use in treatment-naive children when clinical trial data in children or, more often, in adults have demonstrated optimal and durable efficacy with acceptable toxicity and ease of use, and pediatric studies using surrogate markers have demonstrated safety and appropriate drug exposure. Additional considerations are listed above.

- **Alternative**: Drugs or drug combinations are designated as Alternative for initial therapy when clinical trial data in children or adults show efficacy, but the drugs or drug combinations have disadvantages when compared with Preferred regimens. Drugs or drug combinations may be classified as Alternative for use in treatment-naive children if they are less effective or durable than a Preferred regimen in adults or children; if there are specific toxicity, dosing, formulation, administration, or interaction concerns; or if there is limited experience with the use of these drugs or drug combinations in children.

**Factors to Consider When Selecting an Initial Regimen**

An antiretroviral (ARV) regimen for children should generally consist of two nucleoside reverse transcriptase inhibitors (NRTIs) plus an active drug from one of the following classes: an integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a boosted protease inhibitor (PI). Choice of a regimen should be individualized based on several factors, including the characteristics of the proposed regimen; the patient’s age, weight, sexual maturity rating (SMR), and other characteristics; and the results of drug-resistance testing.

Drug recommendations often include both age and weight limitations. Although age can be used as a rough guide, body weight (when available) is the preferred determinant for selecting a specific drug. An exception to this is infants aged <14 days. Many drugs that are recommended for use in very young infants do not have dosing recommendations for premature infants. Additional information regarding dosing recommendations in this population can be found in *Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection*.

The advantages and disadvantages of each regimen are described in detail in the sections that follow and in Table 8. Additional information regarding the advantages and disadvantages of specific drug combinations can be found in the What to Start section of the Adult and Adolescent Antiretroviral Guidelines. Specific information about the clinical efficacy, adverse events (AEs), and dosing recommendations for each drug can be found in Appendix A: Pediatric Antiretroviral Drug Information. In addition, clinicians should consider potential barriers to adherence. These barriers may include complex dosing schedules, food requirements, the need to use multiple formulations to achieve an appropriate dose, and palatability problems. Counseling patients and caregivers about adherence to therapy is essential for successful ART. The Panel recommends rapid initiation of ART (defined as initiating ART immediately or within days of diagnosis).

Emtricitabine (FTC), lamivudine (3TC), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) have antiviral activity and efficacy against hepatitis B virus (HBV) and should be considered for use in children with HBV/HIV coinfection. For a comprehensive review of this topic, as well as a review of hepatitis C and tuberculosis in patients with HIV, see the Pediatric Opportunistic Infection Guidelines.

**Choosing an Initial Antiretroviral Regimen for Children with HIV**

Preferred regimens for initial therapy include INSTI-based, NNRTI-based, or boosted PI-based regimens. A regimen should be chosen after considering the patient’s individual characteristics (especially age), the results of drug-resistance testing, potential AEs, pill size, and dosing frequency. Adherence to a prescribed regimen is necessary; therefore, the preferences of the patient and caregivers should also be considered when choosing a regimen.

Clinical trial data in children provide some guidance for choosing between an NNRTI-based regimen and a PI-based regimen for initial therapy. Three pediatric studies have compared an NNRTI-based regimen to...
a PI-based regimen, and results varied based on the age of the population studied and the specific drug used within the class.

- The P1060 study demonstrated the superiority of a lopinavir/ritonavir (LPV/r)-based regimen over a nevirapine (NVP)-based regimen in infants and children aged 2 to 35 months, regardless of maternal or infant exposure to peripartum, single-dose NVP prophylaxis. In children with prior NVP exposure, 21.7% of children receiving the LPV/r-based regimen experienced death, virologic failure, or toxicity by Week 24 compared to 39.6% of children receiving the NVP-based regimen. For children with no prior NVP exposure, death, virologic failure, and toxicity occurred in 18.4% of children receiving the LPV/r-based regimen and 40.1% of children receiving the NVP-based regimen.¹

- Those in the NVP group demonstrated greater, but not statistically significant, improvements in CD4 counts and growth parameters. However, improvements in CD4 counts were only maintained up to 1 year after initiation of ART.² Similar improved immune and growth parameters were reported in the NEVEREST study, where these parameters were compared in children who switched to a NVP-containing regimen and those who continued on a LPV/r-containing regimen after achieving virologic suppression.³ Improvements in metabolic parameters have also been seen in children who switched from LPV/r to efavirenz (EFV) at or after 3 years of age.⁴

- PENPACT-1 (PENTA 9/PACTG 390) compared a PI-based regimen and a NNRTI-based regimen in treatment-naive children aged 30 days to <18 years (the study did not dictate the use of specific NNRTIs or PIs). In the PI-based regimen group, 49% of children received LPV/r and 48% received nelfinavir; in the NNRTI-based regimen group, 61% of children received EFV and 38% received NVP. After 4 years of follow-up, 73% of children who were randomized to receive PI-based therapy and 70% who were randomized to receive NNRTI-based therapy remained on their initial ARV regimen. In both groups, 82% of children had viral loads <400 copies/mL.⁵

- The PROMOTE-pediatrics trial demonstrated comparable virologic efficacy among children who were randomized to receive either an NNRTI-based or a LPV/r-based ARV regimen.⁶ Children were aged 2 months to <6 years and had no perinatal exposure to NVP. Selection of the NNRTI was based on age (children aged <3 years received NVP, and those aged ≥3 years primarily received EFV). The proportion of children with viral loads <400 copies/mL at 48 weeks was 80% in the LPV/r arm versus 76% in the NNRTI arm, a difference of 4% that was not statistically significant (95% confidence interval [CI], -9% to +17%).

Clinical investigation of INSTI-based regimens in children has been limited to noncomparative studies that have evaluated the safety, tolerability, and PKs of these drugs. The recommendation for using an INSTI as part of an initial regimen is based largely on extrapolation from adult comparative trials that showed that INSTI-containing regimens have superior efficacy when compared to PI-containing and NNRTI-containing regimens⁷,⁸ and small studies in ART-naive adolescents.⁹

When combined with two NRTIs, the following drugs and drug combinations are considered Preferred regimens for children:

- Children aged <14 days: NVP
- Children aged <14 days and weighing ≥2 kg: Raltegravir (RAL)
- Children aged ≥14 days to <3 years: LPV/r or RAL
- Children aged ≥3 years and
  - Weighing <25 kg: Atazanavir/ritonavir (ATV/r), twice-daily darunavir/ritonavir (DRV/r), or RAL
  - Weighing ≥25 kg: Dolutegravir (DTG)
  - Weighing ≥25 kg: Elvitegravir/cobicistat (EVG/c). Only the fixed-dose combination (FDC) tablet that contains elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/c/FTC/TAF) is recommended at this time.
• Adolescents aged ≥12 years and weighing ≥25 kg: Bictegravir (BIC). BIC is only available as a component of the FDC tablet bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).

Alternative regimens are shown in Table 7 below.

Integrase Strand Transfer Inhibitor-Based Regimens

Four INSTIs—BIC, DTG, EVG, and RAL—are approved by the FDA for treating ARV-naive adults and children with HIV. INSTI-based regimens have quickly become the recommended regimens in adults because of their virologic efficacy, lack of drug interactions, and favorable toxicity profile. RAL is approved for the treatment of infants and children from birth onwards with weights of ≥2 kg. DTG is approved by the FDA for use in children weighing ≥30 kg. The FDC tablet BIC/FTC/TAF (Biktarvy) is approved by the FDA for use in children weighing ≥25 kg. EVG has been studied in adolescents in two FDC regimens and in combination with two NRTIs and ritonavir (RTV) boosting. BIC and DTG, the second-generation INSTIs, have higher barriers to resistance than the first-generation INSTIs RAL and EVG and may have more activity against non-B subtypes of HIV.

Table 8 lists the advantages and disadvantages of using INSTIs. See Appendix A: Pediatric Antiretroviral Drug Information for detailed pediatric information on each drug.

Bictegravir

BIC is available only as part of an FDC tablet that contains BIC 50 mg/FTC 200 mg/TAF 25 mg and is marketed as Biktarvy. BIC/FTC/TAF was approved by the FDA in 2018 for use in adults and in 2019 for use in children or adolescents weighing ≥25 kg. Biktarvy is approved for use in patients who have no ARV treatment history, and it can also be used to replace the current ARV regimen in patients who have been virologically suppressed (viral load <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of the FDC tablet.

Biktarvy was administered to adolescents aged 12 years to <18 years and weighing ≥35 kg who had maintained viral loads <50 copies/mL for ≥6 months. The drug was well tolerated; all 24 participants in the study had viral loads <50 copies/mL at Week 24, and drug exposure in these adolescent patients was similar to the exposure observed in adults. Another study demonstrated the efficacy and tolerability of Biktarvy in children aged 6 years to <12 years who weighed ≥25 kg, although serum trough concentrations were more variable in this child cohort than in adolescent or adult cohorts.

The two studies described above were combined and continued for 48 weeks, at which time 74 of 75 participants had viral loads <50 copies/mL. Recommendation:

• BIC/FTC/TAF is recommended as a Preferred INSTI-based regimen for adolescents aged ≥12 years and weighing ≥25 kg (AI*) and as an Alternative INSTI-based regimen for children aged ≥6 years and weighing ≥25 kg (AI*). The Panel bases this recommendation on the virologic potency and safety profile observed for this combination in adult and pediatric studies.

Dolutegravir

The FDA has approved DTG for use in children weighing ≥30 kg. The approval was supported by data from a study of 46 treatment-experienced (but INSTI-naive) adolescents and 11 treatment-experienced (but INSTI-naive) children aged ≥6 years. The World Health Organization (WHO) recommends using DTG in children weighing ≥20 kg. This recommendation is based on PK and safety data from two ongoing clinical trials (IMPAACT P1093 and ODYSSEY). The Panel agrees with the WHO assessment that DTG can be used in children weighing ≥20 kg (see the Dolutegravir section in Appendix A: Pediatric Antiretroviral Drug Information). DTG has a very favorable safety profile and can be given once daily to treat INSTI-naive patients. Studies of DTG are ongoing in children as young as 4 weeks of age.
In a prospective surveillance study of birth outcomes among pregnant women on ART in Botswana, a small but significant increase in the risk of neural tube defects (NTDs) was observed among infants born to women who were receiving DTG at the time of conception. Specific recommendations about the initiation and use of DTG in adults and adolescents of childbearing potential and in those who are pregnant or trying to conceive are available in the Adult and Adolescent Antiretroviral Guidelines (see Table 6b and Adolescents and Young Adults with HIV) and in the Perinatal Guidelines (see Teratogenicity, Recommendations for Use of Antiretroviral Drugs During Pregnancy, and Appendix D: Dolutegravir Counseling Guide for Health Care Providers).

Recommendation:

- DTG plus a two-NRTI backbone is recommended as a Preferred INSTI-based regimen for children and adolescents aged ≥ 3 years and weighing ≥25 kg (AI*). The Panel bases this recommendation on the virologic potency and safety profile observed for this combination in adult and pediatric studies.

- DTG plus a two-NRTI backbone is recommended as an Alternative INSTI-based regimen for children aged ≥3 years and weighing ≥20 kg to < 25 kg (AI*). Data are limited on the efficacy and safety of using DTG in this weight group, and DTG PKs vary more among children in this weight group than among those weighing ≥25 kg.

- In light of concerns about the potential increased risk of NTDs with the use of DTG, pediatric and adolescent care providers should discuss this risk with patients who are receiving or initiating DTG and their caregivers so they can make informed decisions about the use of DTG (see Appendix D: Dolutegravir Counseling Guide for Health Care Providers in the Perinatal Guidelines). Specific recommendations about the use of DTG in women of childbearing potential, pregnant women, and women who are trying to conceive are available in the Adult and Adolescent Antiretroviral Guidelines (see Table 6b) and in the Perinatal Guidelines (see Teratogenicity and Recommendations for Use of Antiretroviral Drugs During Pregnancy).

**Elvitegravir**

EVG is an INSTI that is available as a single-drug tablet, an FDC tablet that contains EVG/c/FTC/TDF, and an FDC tablet that contains EVG/c/FTC/TAF. Both FDC tablets are approved by the FDA for use in ART-naive adults with HIV. EVG/c/FTC/TAF is approved for use in ART-naive children and adolescents weighing ≥25 kg. Cobicistat (COBI) is a specific, potent cytochrome P450 (CYP) 3A inhibitor that has no activity against HIV. It is used as a PK enhancer, which allows for once-daily dosing of EVG.

Recommendation:

- EVG/c/FTC/TAF is recommended as a Preferred INSTI-based regimen for children and adolescents weighing ≥25 kg who have creatinine clearance (CrCl) ≥30 mL/min (AI*). The Panel bases this recommendation on the virologic potency and safety profile observed for this combination in adult and adolescent studies.

**Raltegravir**

RAL is approved by the FDA for treatment of infants and children weighing ≥2 kg, and it can be used starting at birth. It is available in film-coated tablets, chewable tablets, and single-use packets of granules for oral suspension. Clinicians should consult with an expert in pediatric HIV infection when initiating RAL-based treatment regimens in neonates, infants, and very young children. Additional information can be found in Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection.

Recommendation:

- RAL plus a two-NRTI backbone is recommended as a Preferred INSTI-based regimen for infants and children from birth to age 3 years who weigh ≥2 kg and for children aged ≥3 years and weighing <25 kg.
(AI*). It is an Alternative INSTI-based regimen for children aged ≥3 years and weighing ≥25 kg (AI*). The Panel bases this recommendation on data from randomized clinical trials in adults and pediatric studies that were performed largely in ARV-experienced children and adolescents. The Panel acknowledges that data regarding the efficacy of this agent in those aged <2 years are currently very limited.

- At this time, the Panel does not recommend once-daily dosing of RAL for initial therapy in children and infants.

**Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens**

EFV (for children aged ≥3 months), etravirine (ETR; for children aged ≥6 years), NVP (for children aged ≥15 days), and rilpivirine (RPV; for children aged ≥12 years) have been approved by the FDA for treatment of HIV infection in pediatric patients. NNRTIs have a long half-life that allows for less-frequent drug administration, a lower risk of dyslipidemia and fat maldistribution than some agents in the PI class, and, generally, a lower pill burden than PIs. However, a single viral mutation can confer high-level drug resistance to all NNRTIs except ETR, and cross-resistance to other NNRTIs is common. Rare, but serious and potentially life-threatening, skin and hepatic toxicity can occur with the use of all NNRTI drugs, but these AEs are most frequently observed in patients taking NVP, at least among adults with HIV. NNRTIs have the potential to interact with other drugs that are also metabolized via hepatic enzymes; however, these drug interactions are less frequent with NNRTIs than with boosted-PI regimens. Table 8 lists the advantages and disadvantages of using NNRTIs. See Appendix A: Pediatric Antiretroviral Drug Information for detailed pediatric information for each drug.

**Efavirenz**

Although EFV dosing recommendations are available for patients aged ≥3 months and weighing ≥3.5 kg, the Panel does not endorse the use of this drug in infants and children aged 3 months to 3 years because the PKs of EFV in very young patients can be highly variable.

**Recommendation:**

- EFV plus a two-NRTI backbone is recommended as an Alternative NNRTI-based regimen for initial treatment of HIV in children aged ≥3 years (AI*). The Panel bases this recommendation on studies that evaluated the efficacy and tolerability of this drug in adults and children.

**Nevirapine**

There are extensive clinical and safety data for the use of NVP in children with HIV, and NVP has shown ARV efficacy when used as a component in a variety of combination regimens. NVP has also been used extensively as prophylaxis for the prevention of HIV transmission in young infants during the peripartum period and during breastfeeding. The safety and PKs of NVP have been studied at the low doses of the drug that are used for prophylaxis. There is currently less information available from studies in very young infants about the safety and PKs of the higher NVP doses that are necessary for treatment.

Early testing of infants allows HIV infection to be confirmed before 14 days of age. The Panel recommends the use of NVP as a Preferred NNRTI when a clinician plans to initiate treatment prior to age 14 days. However, there are currently no clinical trial data suggesting that initiating treatment within the first 14 days of life improves outcomes compared to starting after age 14 days. Clinicians should consult an expert in pediatric HIV infection when considering the use of NVP in infants aged <14 days. Additional considerations regarding the use of NVP in infants aged <14 days can be found in Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection.

**Recommendation:**

- NVP plus a two-NRTI backbone is recommended as a Preferred NNRTI-based regimen in infants.
aged <14 days and an *Alternative* NNRTI-based regimen for children aged ≥14 days to <3 years (*AI*). Clinicians should consider switching from NVP to LPV/r or RAL in children aged ≥14 days to <3 years, as these drugs are the *Preferred* ARV agents for this age bracket. LPV/r has better clinical outcomes than NVP in children aged <3 years. The Panel recommends switching from NVP to LPV/r in these patients, because NVP is associated with rare occurrences of significant hypersensitivity reactions (HSRs), including Stevens-Johnson syndrome, and rare (but potentially life-threatening) instances of hepatitis. NVP also has a low barrier to resistance, and there is conflicting data about the virologic efficacy of NVP-based regimens compared to the efficacy of *Preferred* regimens.\(^1,5,61-73\)

**Rilpivirine**

Rilpivirine (RPV) is currently available both as a single-drug tablet and a once-daily FDC tablet that contains FTC/RPV/TDF. The single-drug tablet is approved for use in children and adolescents aged ≥12 years.

**Recommendation:**

- RPV plus a two-NRTI backbone is recommended as an *Alternative* NNRTI-based regimen for children and adolescents aged ≥12 years and weighing ≥35 kg who have HIV viral loads ≤100,000 copies/mL (*AI*). The Panel bases this recommendation on the limited experience with RPV in adolescents and the larger body of evidence in adults.\(^47,74-78\)

**Protease Inhibitor-Based Regimens**

Advantages of PI-based regimens include excellent virologic potency and a high barrier to drug resistance (since multiple mutations are required for a patient to develop resistance). However, because PIs are metabolized via hepatic enzymes, these drugs have the potential for multiple drug interactions. They may also be associated with metabolic complications such as dyslipidemia, fat maldistribution, and insulin resistance. Factors to consider when selecting a PI-based regimen for treatment-naive children include virologic potency, dosing frequency, pill burden, food or fluid requirements, the availability of palatable pediatric formulations, the drug interaction profile, the toxicity profile (particularly toxicities related to metabolic complications), the age of the child, and the availability of data regarding the use of the drug in children. Table 8 lists the advantages and disadvantages of using PIs. See Appendix A: Pediatric Antiretroviral Drug Information for detailed pediatric information on each drug.

RTV is a potent inhibitor of the CYP3A4 isoenzyme and can be used in low doses as a PK booster when coadministered with some PIs, increasing drug exposure by prolonging the half-life of the boosted PI. Currently, only LPV/r is available as a coformulated product. In addition, the use of RTV boosting increases the risk of hyperlipidemia\(^79\) and drug interactions. COBI is an alternative CYP3A4 inhibitor that can also be used as a booster. It is available in a single-drug tablet and in coformulations with ATV and with DRV. Currently, the single-drug tablet is approved by the FDA for administration with ATV in children weighing ≥35 kg and for administration with DRV in children weighing ≥40 kg.

*Preferred* and *Alternative* PIs are presented in alphabetical order below.

**Atazanavir Boosted with Ritonavir or Cobicistat**

ATV is a once-daily PI that was approved by the FDA in March 2008 for use in combination with a two-NRTI backbone in children aged ≥6 years. ATV is most often boosted with RTV. Approval was extended in 2014 for use in infants and children aged ≥3 months and weighing ≥5 kg.\(^80,81\) ATV administered in combination with COBI has been approved by the FDA for use in adults and, using the single-agent COBI tablet, in children weighing ≥35 kg.

**Recommendation:**

- ATV/r plus a two-NRTI backbone is recommended as a *Preferred* PI-based regimen for children aged ≥3 years and weighing <25 kg. It is an *Alternative* PI-based regimen for children aged ≥3 months to <3
years and children aged ≥3 years and weighing ≥25 kg (AI*). Atazanavir/cobicistat plus a two-NRTI backbone is an Alternative PI-based regimen for children weighing ≥35 kg. These regimens have been shown to be virologically potent in adult and pediatric studies and have been well tolerated in pediatric studies. However, the oral powder formulations of ATV and RTV and the oral solution formulation of RTV can be cumbersome to administer.  

• The Panel does not recommend the use of unboosted ATV.

Darunavir Boosted with Ritonavir or Cobicistat

DRV/r is approved by the FDA for use in ARV-naive and ARV-experienced children aged ≥3 years and weighing ≥10 kg. In addition, once-daily dosing of DRV/r is approved for ARV-naive children aged ≥3 years and weighing ≥10 kg, and for ARV-experienced patients who do not have DRV resistance-associated mutations. Once-daily dosing of DRV/r was investigated during a substudy of a twice-daily dosing trial in children aged 3 years to <12 years. This PK evaluation lasted only 2 weeks, after which the participants switched back to the twice-daily regimen. 89 FDA dosing recommendations are based on PK models from this study, but this dose has never undergone trials for clinical efficacy in this age group. A more recent study also suggested that once-daily DRV/r dosing is acceptable for children and adolescents. In this study, the plasma concentration-time curve for DRV/r was substantially lower than the mean value observed in adults; however, trough levels were similar. Because of these findings, and due to the lack of more information about the efficacy of once-daily DRV/r dosing in ARV-naive and ARV-experienced children aged <12 years, the Panel recommends a twice-daily dose of DRV/r in children aged ≥3 years to <12 years. 90 DRV administered in combination with COBI has been approved by the FDA for use in adults and, using the single-agent COBI tablet, in children weighing ≥40 kg. 91

Recommendation:

• DRV/r plus a two-NRTI backbone is recommended as a Preferred PI-based regimen for children aged ≥3 years and weighing ≥10 kg but <25 kg, and as an Alternative PI-based regimen for children aged ≥3 years and weighing ≥25 kg (AI*). The Panel bases these recommendations on the virologic potency shown by DRV/r in adult and pediatric studies, and this combination’s high barrier to the development of drug resistance and excellent toxicity profile in adults and children. 34,90,92-98

• Based on findings from the DIONE study, once-daily dosing of DRV/r is part of an Alternative PI-based regimen in ARV-naive children and adolescents weighing ≥40 kg (AI*).

• Twice-daily dosing of DRV/r should be used for children aged ≥3 years to <12 years.

• Twice-daily dosing of DRV/r should be used when the following DRV resistance-associated substitutions are present in the HIV protease: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V.

• DRV/c plus a two-NRTI backbone is recommended as an Alternative PI-based regimen for adolescents aged ≥12 years and weighing ≥40 kg who are not sexually mature.

Lopinavir/Ritonavir

LPV/r is approved to treat HIV infection in infants and children with a postmenstrual age ≥42 weeks and postnatal age ≥14 days. Once-daily LPV/r dosing is approved by the FDA for initial therapy in adults, 99 but PK data in children do not support a recommendation for once-daily dosing. 100-102

Recommendation:

• LPV/r plus a two-NRTI backbone is recommended as a Preferred PI-based regimen for infants with a postmenstrual age ≥42 weeks and postnatal age ≥14 days to <3 years (AI) and as an Alternative PI-based regimen in children aged ≥3 years (AI*). This regimen has been shown to be virologically potent in adult and pediatric studies and has been well tolerated in pediatric studies. 23,45,82,83,92,99-101,103-107

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from https://aidsinfo.nih.gov/guidelines on 5/4/2020
Selection of Dual-Nucleoside Reverse Transcriptase Inhibitor Backbone as Part of Initial Combination Therapy

Dual-NRTI combinations form the backbone of combination regimens for both adults and children. Currently, eight NRTIs (zidovudine [ZDV], didanosine [ddI], 3TC, stavudine [d4T], abacavir [ABC], FTC, TDF, and TAF) are approved by the FDA for use in children aged <13 years. Dual-NRTI combinations that have been studied in children include:

- ZDV used in combination with ABC, ddI, or 3TC
- ABC used in combination with 3TC, d4T, or ddI
- FTC used in combination with d4T or ddI
- TDF used in combination with 3TC or FTC
- TAF used in combination with FTC

The Panel no longer recommends using ddI or d4T as part of ARV regimens for children due to the significant toxicities observed when using these drugs and the availability of safer agents. The advantages and disadvantages of the different dual-NRTI backbone options that are recommended for initial therapy in children are listed in Table 8. See What Not to Start for more information. Also, see Appendix A: Pediatric Antiretroviral Drug Information for detailed pediatric information on each drug.

In the dual-NRTI backbones listed below, 3TC and FTC are interchangeable. Both 3TC and FTC are well tolerated and have few AEs. FTC is similar to 3TC and can be substituted for 3TC as one component of a preferred dual-NRTI backbone (i.e., FTC used in combination with ABC, TDF, or ZDV). The main advantage of FTC over 3TC is that it can be administered once-daily as part of an initial regimen. Both 3TC and FTC select for the M184V resistance mutation, which is associated with high-level resistance to both drugs, a modest decrease in susceptibility to ABC, and improved susceptibility to ZDV and TDF as a result of decreased viral fitness.

Dual-Nucleoside Reverse Transcriptase Inhibitor Backbones

Dual-NRTI combinations are presented in alphabetical order below.

Abacavir in Combination with Lamivudine or Emtricitabine

ABC is approved for use in children aged ≥3 months when administered as part of an ARV regimen.

Recommendation:

- ABC plus 3TC or FTC is recommended as the Preferred dual-NRTI combination for children aged ≥3 months (AI). Studies of adults and children have reported virologic efficacy and favorable toxicity profiles for these combinations.

- Once-daily dosing is recommended when using the pill formulation of ABC. Twice-daily dosing of liquid ABC is recommended for initial therapy; a change to once-daily dosing can be considered for clinically stable patients with undetectable viral loads and stable CD4 counts.

Tenofovir Alafenamide in Combination with Emtricitabine

TAF is an oral prodrug of tenofovir. It is approved by the FDA as a component of an FDC tablet that also contains EVG, COBI, and FTC for the treatment of HIV in ARV-naive individuals weighing ≥25 kg who have an estimated CrCl ≥30 mL/min. Additional safety and PK data are available for children aged 6 years to <12 years who are receiving this FDC tablet. An FDC tablet that contains FTC/TAF (Descovy) is also available.
Recommendation:

- FTC/TAF is recommended as a Preferred dual-NRTI combination in children and adolescents weighing ≥25 kg who have estimated CrCl ≥30 mL/min when this combination is used with an INSTI or NNRTI; this combination is considered a Preferred dual-NRTI combination when used with a PI in children and adolescents weighing ≥35 kg who have estimated CrCl ≥30 mL/min (AI*). This combination is also recommended as a Preferred drug combination when used in the single-tablet regimen EVG/c/FTC/TAF for children and adolescents weighing ≥25 kg (AI*). The Panel makes these recommendations because TAF has a lower risk of renal and bone AEs than TDF.27,127

- FTC/TAF is neither approved by the FDA nor recommended for use in combination with a boosted PI in children weighing <35 kg, because this combination has not been adequately studied in this age and weight group.

Tenofovir Disoproxil Fumarate in Combination with Lamivudine or Emtricitabine

TDF is approved by the FDA for use in children and adolescents aged ≥2 years when administered as part of an ARV regimen. Decreases in bone mineral density (BMD) have been observed in adults and children receiving TDF, but the clinical significance of these decreases is unknown.109-112,128,129 Before starting treatment, clinicians should consider whether the benefits of using TDF outweigh the potential risks of decreased BMD.130

Recommendation:

- TDF plus 3TC or FTC is recommended as an Alternative dual-NRTI combination for children aged ≥2 years to 12 years (AI*). The Panel bases this recommendation on the virologic efficacy and ease of dosing of these combinations.109-112,116-119,131-136

Zidovudine in Combination with Abacavir

In a European pediatric study, patients who received ZDV plus ABC had lower rates of viral suppression and a greater number of toxicities that lead to regimen modification than patients who received ABC plus 3TC.108,115

Recommendation:

- ZDV plus ABC is recommended as an Alternative dual-NRTI combination for children aged ≥3 months (BII).

Zidovudine in Combination with Lamivudine or Emtricitabine

ZDV is available as a syrup, a capsule, and a tablet, and it is also available in injectable/intravenous preparations. It is approved by the FDA for treatment of HIV in infants aged ≥4 weeks and for prophylaxis in newborns.

Recommendation:

- ZDV plus 3TC or FTC is recommended as a Preferred dual-NRTI combination for infants and children from birth to age ≤6 years, and an Alternative combination in children aged ≥6 years and adolescents (AI*). However, twice-daily dosing is required for ZDV in children aged ≥6 years. Other NRTIs that only require once-daily dosing in children aged ≥6 years are available.120,137-139

- ZDV plus ABC is recommended as an Alternative dual-NRTI combination for use in children aged ≥3 months (BII). In children aged ≥6 years and adolescents who are not sexually mature (i.e., those with SMRs of 1–3), the Panel recommends ZDV plus 3TC or FTC as an Alternative dual-NRTI combination (BII).
**Figure 1. Preferred Regimen by Age, Weight and Drug Class**

**Patient Age and Weight Class**

<table>
<thead>
<tr>
<th>Birth to &lt;14 Days of Age&lt;sup&gt;a,b,c&lt;/sup&gt;</th>
<th>Children Aged ≥14 Days to &lt;3 Years</th>
<th>Children Aged ≥3 Years and Weighing ≤25 kg</th>
<th>Children Aged ≥3 Years and Weighing ≥25 kg</th>
<th>Adolescents Aged ≥12 Years and Weighing ≥25 kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Two NRTIs plus RAL&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td>Two NRTIs plus BIC&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Two NRTIs plus DTG&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Two NRTIs plus EVG/COB&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td>INSTI-Based Regimens</td>
<td></td>
<td>Two NRTIs plus NVP&lt;sup&gt;g&lt;/sup&gt;</td>
<td>Two NRTIs plus ATV/r&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Two NRTIs plus LPV/r&lt;sup&gt;i&lt;/sup&gt;</td>
<td></td>
<td>Two NRTIs plus DRV/r&lt;sup&gt;j&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NNRTI-Based Regimens</td>
<td></td>
<td>Two NRTIs plus ATV/r&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI-Based Regimens</td>
<td></td>
<td>Two NRTIs plus DRV/r&lt;sup&gt;j&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**a** If treatment is scheduled to begin before a patient is aged 14 days, NVP or RAL are *Preferred* agents because they are the only options with dosing information available for this age group. While many pediatric experts favor initiating ART as soon as possible after birth in order to limit the establishment of viral reservoirs, available clinical trial data does not suggest that initiating treatment within the first 14 days of life leads to better clinical outcomes than initiating treatment after 14 days of age. Clinicians should consult an expert in pediatric HIV infection before initiating treatment in infants aged <14 days. Additional considerations regarding the use of NVP or RAL in infants aged <14 days can be found in Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection. Switching from NVP to LPV/r should be considered when the infant is aged ≥14 days with a postmenstrual age of 42 weeks (the span of time between the first day of the mother’s last menstrual period and birth, plus the time elapsed after birth); LPV/r has produced better clinical outcomes in studies of children aged <3 years than NVP. Data are limited on the clinical outcomes of using RAL in infants and children aged <2 years.

**b** In general, LPV/r *should not be administered* to neonates before a postmenstrual age of 42 weeks and a postnatal age of ≥14 days (see the Lopinavir/Ritonavir section in Appendix A: Pediatric Antiretroviral Drug Information).

**c** RAL can be used in infants weighing ≥2 kg. RAL pills or chewable tablets can be used in children aged ≥2 years. Granules can be administered to infants and children from birth to age 2 years.

**d** BIC is available only as part of an FDC tablet that contains BIC/FTC/TAF; this FDC tablet is recommended as a *Preferred* regimen for adolescents aged ≥12 years and weighing ≥25 kg. It is recommended as an *Alternative* regimen for children aged ≥6 years and weighing ≥25 kg.

**e** DTG is recommended as a *Preferred* agent only for children and adolescents aged ≥3 years and weighing ≥25 kg. It is recommended as an *Alternative* agent in children aged ≥3 years and weighing 20 kg to <25 kg. For children weighing <20 kg, the use of RAL can be considered when an INSTI-based regimen is desired.

**f** EVG is currently recommended only as a component of FDC tablets. Tablets containing EVG/c/FTC/TAF are recommended as a *Preferred* regimen for children and adolescents weighing ≥25 kg.

**g** NVP should not be used in post-pubertal girls with CD4 counts >250/mm³, unless the benefit clearly outweighs the risk. NVP is approved by the FDA for the treatment of infants aged ≥15 days.

**h** Once-daily DRV should not be used in children aged <12 years or weighing <40 kg. Once-daily DRV should also not be used when any one of the following resistance-associated substitutions are present: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V. DRV/r is recommended as an *Alternative* drug combination for children aged ≥6 years to <12 years, because there are other drugs that can be administered once daily. This combination is considered a *Preferred* option for adolescents aged ≥12 years with SMRs of 1–3 when once-daily administration is possible.

**Key:** ART = antiretroviral therapy; ATV/r = atazanavir/ritonavir; BIC = bictegravir; CD4 = CD4 T lymphocyte; COBI = cobicistat; DRV = darunavir; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FDA = Food and Drug Administration; FDC = fixed-dose combination; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; SMR = sexual maturity rating; TAF = tenofovir alafenamide

*Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection*
Table 7. Antiretroviral Regimens Recommended for Initial Therapy for HIV Infection in Children

An ARV regimen for treatment-naive children is generally made up of a two-NRTI backbone and either one NNRTI or one INSTI or one PI boosted with RTV or COBI. Regimens are designated Preferred based on efficacy, ease of administration, and acceptable toxicity. Alternative regimens have also demonstrated efficacy, but clinical experience with these regimens is limited or these regimens are more difficult to administer than Preferred regimens. Regimens should be tailored to the individual patient by weighing the advantages and disadvantages of each combination. Many agents have multiple formulations and age and weight recommendations. Please consult Appendix A: Pediatric Antiretroviral Drug Information for additional information and recommended doses and formulations (see Table 8 below).

Children who are receiving effective and tolerable ARV regimens can continue using those regimens as they age, even if the combinations they are receiving are no longer Preferred regimens.

### Preferred Regimens

<table>
<thead>
<tr>
<th>Age</th>
<th>Regimens</th>
<th>FDC Available (see Appendix A, Table 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants, Birth to Age &lt;14 Daysa,b</td>
<td>Two NRTIs plus NVP</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Weight ≥2 kg Two NRTIs plus RALc No</td>
<td>No</td>
</tr>
<tr>
<td>Children Aged ≥14 Days to &lt;3 Years</td>
<td>Two NRTIs plus LPV/rb</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Weight ≥2 kg Two NRTIs plus RALc No</td>
<td>No</td>
</tr>
<tr>
<td>Children Aged ≥3 Years</td>
<td>Weight &lt;25 kg Two NRTIs plus ATV/r</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Two NRTIs plus twice-daily DRV/rd</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Two NRTIs plus RALc No</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Weight ≥25 kg Two NRTIs plus DTG²</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Two NRTIs plus EVG/c¹</td>
<td>Yes</td>
</tr>
<tr>
<td>Adolescents Aged ≥12 Years with SMRs of 1–3</td>
<td>Weight ≥25 kg Two NRTIs plus BIC²</td>
<td>Yes</td>
</tr>
<tr>
<td>Adolescents Aged ≥12 Years with SMRs of 4 or 5</td>
<td>Refer to the Adult and Adolescent Antiretroviral Guidelines</td>
<td>Yes</td>
</tr>
</tbody>
</table>

### Alternative Regimens

<table>
<thead>
<tr>
<th>Age</th>
<th>Regimens</th>
<th>FDC Available (see Appendix A, Table 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children Aged ≥14 Days to &lt;3 Years</td>
<td>Two NRTIs plus NVPa</td>
<td>No</td>
</tr>
<tr>
<td>Children Aged ≥3 Months to &lt;3 Years</td>
<td>Two NRTIs plus ATV/r</td>
<td>No</td>
</tr>
<tr>
<td>Children Aged ≥3 Years</td>
<td>Weight ≥20 kg to &lt;25 kg Two NRTIs plus DTG²</td>
<td>No</td>
</tr>
<tr>
<td>Children Aged ≥3 Years</td>
<td>Weight ≥25 kg Two NRTIs plus ATV/r</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Two NRTIs plus DRV/rd</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Two NRTIs plus RALc No</td>
<td>No</td>
</tr>
<tr>
<td>Children Aged ≥3 Years</td>
<td>Two NRTIs plus EFV</td>
<td>No³</td>
</tr>
<tr>
<td></td>
<td>Two NRTIs plus LPV/r</td>
<td>No</td>
</tr>
<tr>
<td>Children Aged ≥6 Years to &lt;12 Years</td>
<td>Weight ≥25 kg Two NRTIs plus BIC²</td>
<td>Yes</td>
</tr>
<tr>
<td>Adolescents Aged ≥12 Years with SMRs of 1–3</td>
<td>Weight ≥35 kg Two NRTIs plus RPV³</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Two NRTIs plus ATV/c</td>
<td>No³</td>
</tr>
<tr>
<td></td>
<td>Two NRTIs plus DRV/c¹</td>
<td>Yes</td>
</tr>
<tr>
<td>Adolescents Aged ≥12 Years with SMRs of 4 or 5</td>
<td>Refer to the Adult and Adolescent Antiretroviral Guidelines</td>
<td>Yes</td>
</tr>
</tbody>
</table>

### Preferred Dual-NRTI Backbone Options for Use in Combination with Other Drugs

<table>
<thead>
<tr>
<th>Age</th>
<th>Dual-NRTI Backbone Options</th>
<th>FDC Available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children, Birth to Age &lt;3 Months</td>
<td>ZDV plus (3TC or FTC)³</td>
<td>No³</td>
</tr>
</tbody>
</table>
Table 7. Antiretroviral Regimens Recommended for Initial Therapy for HIV Infection in Children, continued

<table>
<thead>
<tr>
<th>Preferred Dual-NRTI Backbone Options for Use in Combination with Other Drugs, continued</th>
<th>Age</th>
<th>Dual-NRTI Backbone Options</th>
<th>FDC Available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children Aged ≥3 Months to &lt;6 Years</td>
<td>ABC plus (3TC or FTC)</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ZDV plus (3TC or FTC)</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Children and Adolescents Aged ≥6 Years with SMRs of 1–3</td>
<td>ABC plus (3TC or FTC)</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weighing ≥25 kg and receiving a regimen that contains an INSTI or an NNRTI</td>
<td>FTC/TAF</td>
<td>Yes</td>
</tr>
<tr>
<td>Adolescents Aged ≥12 Years with SMRs of 4 or 5</td>
<td>Refer to the Adult and Adolescent Antiretroviral Guidelines</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Alternative Dual-NRTI Backbone Options for Use in Combination with Other Drugs</td>
<td>Age</td>
<td>Dual-NRTI Backbone Options</td>
<td>FDC Available</td>
</tr>
<tr>
<td>Children Aged ≥3 Months</td>
<td>ZDV plus ABC</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Children Aged ≥2 Years to 12 Years</td>
<td>TDF plus (3TC or FTC)</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Children and Adolescents Aged ≥6 Years and SMRs of 1–3</td>
<td>ZDV plus (3TC or FTC)</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>

* If treatment is scheduled to begin before a patient is aged 14 days, NVP or RAL are Preferred agents because they are the only options with dosing information available for this age group. While many pediatric experts favor initiating ART as soon as possible after birth in order to limit the establishment of viral reservoirs, available clinical trial data does not suggest that initiating treatment within the first 14 days of life leads to better clinical outcomes than initiating treatment after 14 days of age. Clinicians should consult an expert in pediatric HIV infection before initiating treatment in infants aged <14 days. Additional considerations regarding the use of NVP or RAL in infants aged <14 days can be found in Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection. Switching from NVP to LPV/r should be considered when the infant is aged ≥14 days with a postmenstrual age of 42 weeks (the span of time between the first day of the mother’s last menstrual period and birth, plus the time elapsed after birth); LPV/r has produced better clinical outcomes in studies of children aged <3 years than NVP. Data are limited on the clinical outcomes of using RAL in infants and children aged <2 years.

In general, LPV/r should not be administered to neonates before a postmenstrual age of 42 weeks and postnatal age ≥14 days (see the Lopinavir/Ritonavir section in Appendix A: Pediatric Antiretroviral Drug Information).

RAL pills or chewable tablets can be used in children aged ≥2 years. Granules can be administered in infants and children from birth to age 2 years. No dosing information is available for preterm infants or those weighing <2 kg at birth.

DRV should only be used in children weighing ≥10 kg. Once-daily DRV should not be used in children aged <12 years or weighing <40 kg. Once-daily DRV should also not be used when any one of the following resistance-associated substitutions are present: V111, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V. DRV/r is recommended as an Alternative drug combination for children aged ≥6 years to <12 years and weighing ≥25 kg, because there are other drugs that can be administered once daily and that are better tolerated. Note that DRV/r can be administered once daily in adolescents aged ≥12 years and weighing ≥40 kg who are not sexually mature (SMR 1–3).

DTG is recommended as a Preferred agent for children and adolescents aged ≥3 years and weighing ≥25 kg. It is recommended as an Alternative agent in children aged ≥3 years and weighing 20 kg to <25 kg. An FDC tablet that contains ABC/DTG/3TC (Triumeq) is available for children weighing ≥25 kg.

EVC is currently recommended only as a component of FDC tablets. Tablets that contain EVG/c/FTC/TAF (Genvoya) are recommended as a Preferred regimen for children and adolescents weighing ≥25 kg.

BIC is available only as part of an FDC tablet that contains BIC/FTC/TAF (Biktarvy); this FDC tablet is recommended as a Preferred regimen for adolescents aged ≥12 years and weighing ≥25 kg. It is recommended as an Alternative regimen for children aged ≥6 years and weighing ≥25 kg.

NVP should not be used in post-pubertal girls with CD4 counts ≥250/mm³, unless the benefit clearly outweighs the risk. NVP is approved by the FDA for treatment of infants aged ≥15 days.

EFV is approved by the FDA for use in children aged ≥3 months and weighing ≥3.5 kg, but it is not recommended by the Panel for initial therapy in children aged ≥3 months to 3 years. FDC tablets that contain EFV/FTC/TDF (Atripla) and EFV 600 mg/3TC/TDF (Symfi) are available. See the Efavirenz section in Appendix A: Pediatric Antiretroviral Drug Information for information about use of the FDC EFV 400 mg/3TC/TDF (Symfi Lo).

FDA-approved FDC tablets are not included in this table when they are not approved for use in the specific patient populations being discussed.

RPV should be administered to adolescents aged ≥12 years and weighing ≥35 kg who have initial viral loads ≤100,000 copies/mL. FDC tablets that contain FTC/RPV/TAF (Odefsey) and FTC/RPV/TDF (Complera) are available.
Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children

<table>
<thead>
<tr>
<th>ARV Class</th>
<th>ARV Agent(s)</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSTIs</td>
<td>All INSTIs</td>
<td><strong>INSTI Class Advantages:</strong> • Few drug-drug interactions • Well-tolerated</td>
<td><strong>INSTI Class Disadvantages:</strong> • Limited data on pediatric dosing or safety</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The FDC tablet is <strong>not recommended</strong> for patients with hepatic impairment or an estimated CrCl &lt;30 mL/min.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The FDC tablet <strong>should not be coadministered</strong> with rifampin or doxefilide.</td>
</tr>
<tr>
<td>BIC</td>
<td>Once-daily administration</td>
<td>Can give with or without food</td>
<td>Available in FDC tablets (see Appendix A, Table 1)</td>
</tr>
<tr>
<td>DTG</td>
<td>Once-daily administration</td>
<td>Can give with food</td>
<td>Available in FDC tablets (see Appendix A, Table 1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Single-agent DTG pills are available in several doses and are small in size.</td>
<td>Drug interactions with EFV, FPV/r, TPV/r, and rifampin, necessitating twice-daily dosing of DTG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CNS side effects, particularly sleep disturbances and possible increased risk of NTDs in infants born to women who were receiving DTG at the time of conception</td>
</tr>
<tr>
<td>EVG</td>
<td>Once-daily administration</td>
<td></td>
<td>Among INSTIs, EVG has the lowest barrier to the development of resistance.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If EVG is coadministered with COBI, there is potential for multiple drug interactions because COBI is metabolized by hepatic enzymes (e.g., CYP3A4).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>COBI inhibits tubular secretion of creatinine, and this may result in increased serum creatinine but normal glomerular clearance.</td>
</tr>
</tbody>
</table>

Key: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; ATV/c = atazanavir/cobicistat; ATV/r = atazanavir/ritonavir; BIC = bictegravir; CD4 = CD4 T lymphocyte; COBI = cobicistat; DRV = darunavir; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FDA = Food and Drug Administration; FDC = fixed-dose combination; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; NVP = nevirapine; the Panel = the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SMR = sexual maturity rating; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine
Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children (page 2 of 4)

<table>
<thead>
<tr>
<th>ARV Class</th>
<th>ARV Agent(s)</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSTIs</td>
<td>RAL</td>
<td>Can give with food</td>
<td>Potential for rare systemic allergic reaction or hepatitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Available in tablet, chewable tablet, and powder formulations</td>
<td>Granule formulation requires a multistep preparation before administration; caregiver must be taught how to properly prepare this formulation.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Once-daily administration (with RAL HD) can be used for treatment-naive or virologically suppressed children weighing ≥ 40 kg.</td>
<td></td>
</tr>
<tr>
<td>NNRTIs</td>
<td>All NNRTIs</td>
<td>NNRTI Class Advantages:</td>
<td>NNRTI Class Disadvantages:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Long half-life</td>
<td>• A single mutation can confer resistance, with cross-resistance between EFV and NVP.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Lower risk of dyslipidemia and fat maldistribution than PIs</td>
<td>• Rare but serious and potentially life-threatening cases of skin rash, including SJS, and hepatic toxicity. All NNRTIs pose this risk, but the risk is greatest with NVP.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• PI-sparing</td>
<td>• Potential for multiple drug interactions due to metabolism via hepatic enzymes (e.g., CYP3A4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Lower pill burden than PIs for children taking the solid formulation; easier to use and adhere to than PI-based regimens</td>
<td></td>
</tr>
<tr>
<td>EFV</td>
<td></td>
<td>Once-daily administration</td>
<td>Neuropsychiatric AEs (bedtime dosing is recommended to reduce CNS effects)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Available in FDC tablets (see Appendix A, Table 1)</td>
<td>Rash (generally mild)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Potent ARV activity</td>
<td>No commercially available liquid formulation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Can give with food (but avoid high-fat meals)</td>
<td>Limited data on dosing for children aged &lt;3 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Capsules can be opened and added to food.</td>
<td>No data on dosing for children aged &lt;3 months</td>
</tr>
<tr>
<td>NVP</td>
<td></td>
<td>Liquid formulation is available.</td>
<td>Reduced virologic efficacy in young infants, regardless of exposure to NVP as part of a peripartum preventive regimen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dosing information for young infants is available.</td>
<td>Higher incidence of rash/HSR than other NNRTIs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Can give with food</td>
<td>Higher rates of serious hepatic toxicity than EFV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Extended-release formulation is available that allows for once-daily dosing in older children.</td>
<td>Decreased virologic response compared with EFV</td>
</tr>
<tr>
<td>RPV</td>
<td></td>
<td>Once-daily dosing</td>
<td>Twice-daily dosing necessary in children with BSA &lt; 0.58 m²</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Available in FDC tablets (see Appendix A, Table 1)</td>
<td>Low barrier to resistance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Should not use in patients with viral loads &gt; 100,000 copies/mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Must be taken with a ≥ 500 kcal meal at a consistent time each day; this may affect adherence.</td>
<td>Low barrier to resistance</td>
</tr>
<tr>
<td>PIs</td>
<td>All PIs</td>
<td>PI Class Advantages:</td>
<td>PI Class Disadvantages:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• NNRTI-sparing</td>
<td>• Metabolic complications, including dyslipidemia, fat maldistribution, and insulin resistance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clinical, virologic, and immunologic efficacy are well-documented.</td>
<td>• Potential for multiple drug interactions because of metabolism via hepatic enzymes (e.g., CYP3A4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Resistance to PIs requires multiple mutations.</td>
<td>• Higher pill burden than NRTI-based or NNRTI-based regimens for patients taking solid formulations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• When combined with a dual-NRTI backbone, a regimen that contains a PI targets HIV at two steps of viral replication by inhibiting the activity of viral reverse transcriptase and protease enzymes.</td>
<td>• Poor palatability of liquid preparations, which may affect adherence</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Most PIs require RTV boosting, resulting in drug interactions that are associated with RTV</td>
</tr>
</tbody>
</table>
Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children (page 3 of 4)

<table>
<thead>
<tr>
<th>ARV Class</th>
<th>ARV Agent(s)</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boosted ATV</td>
<td>Once-daily dosing</td>
<td>No liquid formulation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Powder formulation is available.</td>
<td>Should be administered with food</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ATV has less effect on TG and total cholesterol levels than other PIs (but RTV boosting may be associated with elevations in these parameters).</td>
<td>Indirect hyperbilirubinemia is common, but asymptomatic. Scleral icterus may be distressing to the patient, which may affect adherence.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Must be used with caution in patients with pre-existing conduction system defects (can prolong PR interval of ECG).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>RTV is associated with a large number of drug interactions.</td>
</tr>
<tr>
<td></td>
<td>Boosted DRV</td>
<td>Can be used once daily in children aged ≥12 years</td>
<td>Pediatric pill burden high with current tablet dose formulations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Liquid formulation is available.</td>
<td>Should be administered with food</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DRV requires a boosting agent.</td>
<td>Must be boosted to achieve adequate plasma concentrations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Available in FDC tablets (see Appendix A, Table 1)</td>
<td>Contains sulfonamide. The potential for cross-sensitivity between DRV and other drugs in sulfonamide class is unknown.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>RTV is associated with a large number of drug interactions.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Can only be used once daily in the absence of certain PI-associated resistance mutations</td>
</tr>
<tr>
<td></td>
<td>LPV/r</td>
<td>LPV is only available coformulated with RTV in liquid and tablet formulations.</td>
<td>Poor palatability of liquid formulation (bitter taste).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tablets can be given without regard to food, but they may be tolerated better when taken with meal or snack.</td>
<td>Liquid formulation should be administered with food.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>RTV is associated with a large number of drug interactions.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Should not be administered to neonates before a postmenstrual age of 42 weeks (the span of time between the first day of the mother's last menstrual period and birth, plus the time elapsed after birth) and a postnatal age ≥14 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Must be used with caution in patients with pre-existing conduction system defects (can prolong PR and QT interval of ECG)</td>
</tr>
<tr>
<td>Dual-NRTI Backbones</td>
<td>ABC plus (3TC or FTC)</td>
<td>Palatable liquid formulations</td>
<td>Risk of ABC HSR; perform HLA-B*5701 screening before initiating ABC.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Can give with food</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Available in FDC tablets (see Appendix A, Table 1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FTC/TAF for children aged ≥6 years</td>
<td>Once-daily dosing</td>
<td>Limited data on the safety and efficacy of this combination in children</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Small tablet size</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lower risk of TFV-associated renal and bone toxicity with TAF than with TDF in adults</td>
<td>Increase lipid levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Available in FDC tablets (see Appendix A, Table 1)</td>
<td></td>
</tr>
</tbody>
</table>
Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children

<table>
<thead>
<tr>
<th>ARV Class</th>
<th>ARV Agent(s)</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dual-NRTI Backbones</td>
<td>TDF plus</td>
<td>Once-daily dosing for TDF</td>
<td>Limited pediatric experience</td>
</tr>
<tr>
<td>In Alphabetical Order,</td>
<td>(3TC or FTC)</td>
<td>Resistance is slow to develop.</td>
<td>Potential bone and renal toxicity</td>
</tr>
<tr>
<td>continued</td>
<td>for</td>
<td>Lower risk of mitochondrial toxicity than other NRTIs</td>
<td>Appropriate dosing is complicated by numerous drug-drug interactions with other ARV agents,</td>
</tr>
<tr>
<td></td>
<td>adolescents</td>
<td>Can give with food</td>
<td>including ddI, LPV/r, ATV, and TPV.</td>
</tr>
<tr>
<td></td>
<td>with SMRs of</td>
<td>Available as reduced-strength tablets and oral powder for use in younger children</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4 or 5</td>
<td>Available in FDC tablets (see Appendix A, Table 1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZDV plus</td>
<td></td>
<td>Extensive pediatric experience</td>
<td>Bone marrow suppression and lipoatrophy with ZDV</td>
</tr>
<tr>
<td>(3TC or FTC)</td>
<td></td>
<td>Coformulations of ZDV and 3TC are available (Combivir and generic) for children weighing ≥30 kg.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Palatable liquid formulations</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Can give with food</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>FTC is available as a palatable liquid formulation that can be administered once daily.</td>
<td></td>
</tr>
<tr>
<td>ZDV plus</td>
<td></td>
<td>Palatable liquid formulations</td>
<td>Risk of ABC HSR; perform HLA-B*5701 screening before initiating ABC.</td>
</tr>
<tr>
<td>ABC</td>
<td></td>
<td>Can give with food</td>
<td>Bone marrow suppression and lipoatrophy with ZDV</td>
</tr>
</tbody>
</table>

Key: 3TC = lamivudine; ABC = abacavir; AE = adverse event; ARV = antiretroviral; ATV = atazanavir; BIC = bictegravir; BSA = body surface area; CNS = central nervous system; COBI = cobicistat; CrCl = creatinine clearance; CYP = cytochrome P450; ddI = didanosine; DRV = darunavir; DTG = dolutegravir; ECQ = electrocardiogram; EFV = efavirenz; EVG = elvitegravir; FDC = fixed-dose combination; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; HD = high dose; HSR = hypersensitivity reaction; INSTI = integrase strand transfer inhibitor; LPV = lopinavir; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NTD = neural tube defect; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SJS = Stevens-Johnson Syndrome; SMR = sexual maturity rating; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TFV = tenofovir; TG = triglyceride; TPV = tipranavir; TPV/r = tipranavir/ritonavir; ZDV = zidovudine

References


57. Zugar A. Studies disagree on frequency of late CNS side effects from efavirenz. *AIDS Clin Care.* 2006;4(1).


84. Kiser JJ, Fletcher CV, Flynn PM, et al. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil...


132. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with


